Embecta (NASDAQ:EMBC) Receives "Buy" Rating from BTIG Research

Key Points

• Embecta's stock has received a "buy" rating from BTIG Research, with a price target of $25.00, indicating a potential upside of 67.11% from its current price.
• The company reported **$1.12 earnings per share**, significantly beating the consensus estimate of $0.77, and posted quarterly revenue of $295.50 million, surpassing analyst expectations.
• Embecta's current average rating is a "Moderate Buy" with a predicted price target of **$19.00**, with various analysts offering differing ratings from "Strong Buy" to "Hold".

BTIG Research reissued their buy rating on shares of Embecta (NASDAQ:EMBC - Free Report) in a research note released on Friday, September 5th,Benzinga reports. The firm currently has a $25.00 price objective on the stock.

Several other research firms have also issued reports on EMBC. Wall Street Zen raised Embecta from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 16th. Zacks Research raised Embecta from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 26th. Finally, Mizuho reduced their target price on Embecta from $13.00 to $12.00 and set a "neutral" rating on the stock in a report on Wednesday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $19.00.

Embecta Stock Performance

EMBC traded down $0.30 during trading hours on Friday, reaching $15.01. The company's stock had a trading volume of 332,878 shares, compared to its average volume of 482,119. Embecta has a 52 week low of $9.20 and a 52 week high of $21.48. The company's 50-day moving average is $12.38 and its 200-day moving average is $11.92. The firm has a market cap of $877.93 million, a PE ratio of 10.50, a price-to-earnings-growth ratio of 0.85 and a beta of 1.12.

Embecta (NASDAQ:EMBC - Get Free Report) last posted its quarterly earnings data on Friday, August 8th. The company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.35. The firm had revenue of $295.50 million for the quarter, compared to analysts' expectations of $278.15 million. Embecta had a negative return on equity of 23.40% and a net margin of 7.58%.The company's quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.74 EPS. Embecta has set its FY 2025 guidance at 2.900-2.950 EPS. Equities analysts anticipate that Embecta will post 2.85 earnings per share for the current fiscal year.

Embecta Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, September 15th. Stockholders of record on Friday, August 29th will be paid a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 4.0%. The ex-dividend date of this dividend is Friday, August 29th. Embecta's dividend payout ratio (DPR) is presently 41.96%.

Institutional Trading of Embecta

Hedge funds have recently made changes to their positions in the company. Banque Transatlantique SA boosted its stake in shares of Embecta by 879.1% during the first quarter. Banque Transatlantique SA now owns 3,701 shares of the company's stock valued at $44,000 after purchasing an additional 3,323 shares in the last quarter. Brooklyn Investment Group boosted its stake in shares of Embecta by 1,164.1% during the first quarter. Brooklyn Investment Group now owns 3,590 shares of the company's stock valued at $46,000 after purchasing an additional 3,306 shares in the last quarter. Wealthquest Corp bought a new position in shares of Embecta during the first quarter worth about $48,000. Picton Mahoney Asset Management bought a new position in shares of Embecta during the first quarter worth about $50,000. Finally, Ameriflex Group Inc. bought a new position in shares of Embecta during the fourth quarter worth about $53,000. 93.83% of the stock is owned by institutional investors and hedge funds.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.